4investors | Börsen-News | Adhoc- und Unternehmensnews | congatec

EMERAM sells its stake in Swiss 3D sensor and analytics company Xovis to Capvis

15.05.2019 (www.4investors.de - in Kooperation mit DGAP - EQS Group):






DGAP-Media / 15.05.2019 / 15:00

Press Release

EMERAM sells its stake in Swiss 3D sensor and analytics company Xovis to Capvis

Zollikofen, Switzerland/Munich, 15 May 2019 - The fund advised by the Munich investment company EMERAM Capital Partners GmbH ("EMERAM") has agreed to sell its stake in Xovis AG ("Xovis") to Capvis Equity V LP, a fund advised by the Swiss private equity firm Capvis AG (together "Capvis"). The parties have agreed not to disclose any financial details of the transaction.

Xovis is the worldwide market leader for the analysis of people flows and waiting times. EMERAM acquired a stake in the company in August 2016. In close cooperation with the founding team, Xovis became the leading provider in its business segments and markets.

In the business segment "Airports", the number of customers has tripled within the last three years. Approximately 75 of the world's largest airports use Xovis' technology, including the airports in Atlanta, Dubai, Frankfurt, Paris, and Delhi. The "Stationary Retail" business segment has also developed very successfully, with three of the world's largest supermarket chains among Xovis' customers. In addition, the business segment "Public Transportation" has been established as a further growth area.

As part of the strengthening of worldwide sales, an office in Boston has been opened in order to access the US market. In the course of the positive operational development of the company, the number of employees rose from 34 in June 2016 to almost 90 today. Moreover, investments in innovations increased and, in 2018, Xovis celebrated a world first with the introduction of the first sensor with AI characteristics.

David Studer, CEO of Xovis, commented: "Together with the EMERAM team, we have strategically and operationally developed Xovis over the past three years. We have further professionalized our financial aspects and consistently strengthened our sales and marketing activities. As a result, we have significantly increased our market penetration with an average growth rate of 40%. In the process, the EMERAM team supported us both as a financial partner and as a valuable sparring partner. We will continue our successful path with our new owner."

Volker Schmidt, founding partner of EMERAM Capital Partners, added: "We would like to thank the management team and all employees for their great cooperation and commitment. Today, Xovis is excellently positioned as a technology leader in a dynamically growing industry. It was our pleasure to support the company for parts of this journey. We are convinced that Xovis will continue its success story."

The three founders and managing directors - Christian Studer, David Studer and Markus Herrli - will remain shareholders of Xovis and will continue to lead the company in the next growth phase.

The EMERAM team included Volker Schmidt, Kai Köppen, Fabian Furtmeier and Matthias Obermeyr. EMERAM was advised by GCA Altium (M&A), Schellenberg Wittmer (Legal) and Alvarez & Marsal (Finance).

About EMERAM Capital Partners

EMERAM is an independent private equity firm for mid-cap companies in the German-speaking area. Funds advised by EMERAM Capital Partners provide capital to drive the development of companies, drawing upon a fund volume of EUR400m. Its team of experienced investment professionals currently oversees seven portfolio companies: Boards & More, Matrix42, diva-e Digital Value Excellence, Xovis, Drahtzug Stein Group, frostkrone Tiefkühlkost and Meona Group.

EMERAM regards itself as a long-term business development partner for companies in five industry sectors: consumer goods, retail, industrial goods, business services and healthcare. The six founding partners combine in-depth market knowledge with operational experience in these sectors. Together, the team has successfully closed over 35 transactions and supported the development of portfolio companies by serving on over 40 advisory boards and supervisory boards. EMERAM Capital Partners was founded as an independent partnership in Munich in 2012.

 

About Xovis AG

Xovis is a Swiss high-tech market and technology leader that develops, produces and distributes 3D sensors and software solutions for the exact counting and analysis of human flows worldwide. The products are used for the optimized control of passenger flows and waiting times, for example at airports or in stationary retail. The unique multi-sensor technology enables the coverage of large areas and provides highest counting accuracy and reliability in accordance with data protection regulations. Xovis's technology is characterized by simple integration, highest precision and AI-based features. The company was founded in 2008 and currently employs around 90 people in Switzerland and the USA. The headquarter is in Zollikofen (Canton Bern, Switzerland).

 

Media contact for EMERAM Capital Partners

Anna Steudel

Kekst CNC
Tel.: +49 172 259 66 20
E-Mail: anna.steudel@kekstcnc.com

 

Media contact for Xovis

David Studer

CEO

Tel.: +41 32 342 04 70

E-Mail: david.studer@xovis.com

 

 


End of Media Release
Issuer: EMERAM Capital Partners GmbH
Key word(s): Finance
15.05.2019 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

811749  15.05.2019 


Weitere DGAP-News von congatec

19.09.2019 - Beno Holding AG: Beno Immobilien GmbH erzielt erhebliche Mieterhöhungen durch Optimierungen im bestehenden Portfolio
19.09.2019 - DGAP-News: fulfin schließt 7-stellige Seed-Finanzierungsrunde ab, um Warenfinanzierung für eCommerce-Händler neu zu definieren
19.09.2019 - DGAP-News: Real I.S. AG legt offenen Publikumsfonds REALISINVEST EUROPA auf
19.09.2019 - DGAP-News: Publikation in Human Vaccines & Immunotherapeutics verdeutlicht die Vorteile von hexavalenten CD40-Agonisten bei der Aktivierung von CD40 in der Immunonkologie
19.09.2019 - ???????Interessenverband Kapitalmarkt KMU fordert einen mehr auf KMU zugeschnittenen Emittentenleitfaden

4investors-News zu congatec

13.09.2019 - congatec will 2019 mit Hilfe von Bryan, Garnier und der Commerzbank an die Börse